Nautilus Biotechnolgy, Inc. Common Stock
NAUTNautilus Biotechnologies, Inc. is a biotechnology company focused on developing advanced platform technologies for protein analysis and drug discovery. The company aims to revolutionize the understanding of complex biological systems by providing highly detailed insights into proteins, which are crucial for understanding disease mechanisms and developing new therapies.
Company News
Nautilus Biotechnology (NAUT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024.
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the TD Cowen 44th Annual Healthcare Conference.
Former Quantapore founder and CEO brings 20 years of proteomics and genomics industry experience to company developing a platform for comprehensively quantifying the proteome Former Quantapore founder and CEO brings 20 years of proteomics and genomics industry experience to company developing a platform for comprehensively quantifying the proteome
SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2023.
